US 11,981,668 B2
Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists
Marcin Kolaczkowski, Wieliczka (PL); Adam Bucki, Przebieczany (PL); Joanna Sniecikowska, Wieliczka (PL); and Monika Marcinkowska, Cracow (PL)
Assigned to ADAMED PHARMA S.A., Czosnow (PL)
Filed by Adamed Pharma S.A., Czosnow (PL)
Filed on May 20, 2021, as Appl. No. 17/326,159.
Application 17/326,159 is a continuation of application No. 16/970,871, granted, now 11,034,688, previously published as PCT/EP2019/054171, filed on Feb. 20, 2019.
Claims priority of application No. 18461519 (EP), filed on Feb. 21, 2018.
Prior Publication US 2021/0276995 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01); A61P 25/28 (2006.01); C07D 403/10 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01)
CPC C07D 417/14 (2013.01) [A61P 25/28 (2018.01); C07D 403/10 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01)] 20 Claims
 
1. A method of antagonizing both 5-HT2A and 5-HT6 receptors in a subject comprising administering to a subject an effective amount of a compound having the structure:

OG Complex Work Unit Chemistry
wherein:
G is CH or N;
R1 is H, C1-C4-alkyl, HO—C1-C4-alkyl or C1-C4-alkyl-O—C1-C4-alkyl;
R2 is selected from group consisting of:
phenyl group unsubstituted or substituted with at least one substituent, or
5- or 6-membered heteroaryl group unsubstituted or substituted with at least one substituent,
wherein the substituent is selected from F, Cl, Br, C1-C4-alkyl-, C1-C4-alkyl-O—
or a pharmaceutically acceptable salt thereof, so as to thereby antagonize both 5-HT2A and 5-HT6 receptors in the subject.